Additional file 2 of Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Additional file 2: Table S2. List of clinical trials with engineered NK cell therapies. N = 53 clinical trials (Phase I, II, or I/II) evaluating the infusion of engineered NK cell therapies in hematological or solid tumor patients were registered on ClinicalTrials.gov until 31–12–2021. Studies are sorted by NK cell source (PB-NK, UCB-NK, iPSCs, NK-92, Unknown). The type of engineered NK products (scFv-CAR-NK, Receptor-CAR-NK, CD16-engineered, or CD16- and scFv-engineered CAR-NK), the engineering method, transgene structure, and the clinical trial design and outcome (when available) are presented. Trial status is updated to August 2022. PB: peripheral blood; UCB: umbilical cord blood; iPSCs: induced pluripotent stem cells; scFv: single-chain variable fragment.附加文件2：表S2。工程化自然杀伤（NK）细胞疗法临床试验列表。截至2021年12月31日，ClinicalTrials.gov平台共注册53项临床试验（I期、II期或I/II期），均针对血液系统肿瘤或实体瘤患者评估工程化NK细胞输注疗法。本列表按NK细胞来源（PB-NK、UCB-NK、诱导多能干细胞（iPSCs）、NK-92、未知）排序，同时列出工程化NK产品类型（单链可变片段（scFv）嵌合抗原受体NK细胞（scFv-CAR-NK）、受体嵌合抗原受体NK细胞（Receptor-CAR-NK）、CD16工程化NK细胞，或CD16与scFv联合工程化CAR-NK细胞）、工程化方法、转基因结构，以及可获取的临床试验设计与结局信息。临床试验状态更新至2022年8月。注：PB指外周血（peripheral blood）；UCB指脐带血（umbilical cord blood）；iPSCs指诱导多能干细胞（induced pluripotent stem cells）；scFv指单链可变片段（single-chain variable fragment）。